FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016404251> ?p ?o ?g. }

• W2016404251 endingPage "422" @default.
• W2016404251 startingPage "413" @default.
• W2016404251 abstract "Hepatic encephalopathy (HE) is a metabolic-neurophysiologicsyndrome that occurs in patients with advanced hepatic disease. One of the main pathogenic mechanisms is represented by circulating toxins produced by the intestinal metabolism of nitrogenous compounds. The therapeutic approach to HE is mainly based on drugs that eliminate ammonia-producing bacteria. The aim of this study was to evaluate the effects of the nonabsorbable antibiotic rifaximin in patients with HE who were intolerant or nonresponsive to treatment with an oral, nonabsorbable disaccharide (lactulose). This uncontrolled, open-label, pilot study was conducted at the University of Bologna, Bologna, Italy. Patients aged ≥ 18 years with histologically proven liver cirrhosis and HE were studied. All patients were intolerant or nonresponsive to previous treatment with lactulose. Rifaximin tablets were administered to patients at a dosage of 400 mg TID for 10 days. The portal systemic encephalopathy (PSE) index was evaluated at enrollment and at the end of the treatment period. Tolerability was assessed using hematology, biochemistry, and urinalysis and by recording adverse effects (AEs). Results: Twenty-six patients (18 men, 8 women; mean [SD] age, 55.8 [8.0] years) were enrolled (intolerants, n = 17; nonresponders, n = 9). All patients completed the study. Significant improvement was shown in most of the 5 components of the PSE index after rifaximin administration in both intolerants and nonresponders. At the end of the 10-day treatment period, the PSE index was significantly reduced in both intolerants and nonresponders. Rifaximin was well tolerated; no clinically relevant AEs were observed during the treatment period. Conclusions: This pilot study of patients with liver cirrhosis and HE who were intolerant or nonresponsive to previous treatment with an oral, nonabsorbable disaccharide suggests that treatment with rifaximin may be considered as an adjuvant or an alternative treatment in reducing HE." @default.
• W2016404251 created "2016-06-24" @default.
• W2016404251 creator A5002218114 @default.
• W2016404251 creator A5012219643 @default.
• W2016404251 creator A5033424480 @default.
• W2016404251 creator A5048924165 @default.
• W2016404251 creator A5074786040 @default.
• W2016404251 creator A5078432545 @default.
• W2016404251 date "2004-09-01" @default.
• W2016404251 modified "2023-09-27" @default.
• W2016404251 title "Clinical effects of rifaximin in patientswith hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: An open-label, pilot study" @default.
• W2016404251 cites W1968044273 @default.
• W2016404251 cites W1993451172 @default.
• W2016404251 cites W1997234777 @default.
• W2016404251 cites W2000268422 @default.
• W2016404251 cites W2019515792 @default.
• W2016404251 cites W2025778359 @default.
• W2016404251 cites W2042474819 @default.
• W2016404251 cites W2045466789 @default.
• W2016404251 cites W2050134921 @default.
• W2016404251 cites W2051702928 @default.
• W2016404251 cites W2068324181 @default.
• W2016404251 cites W2090206816 @default.
• W2016404251 cites W2102592290 @default.
• W2016404251 cites W2135051122 @default.
• W2016404251 cites W2138419487 @default.
• W2016404251 cites W2334982407 @default.
• W2016404251 cites W4247209357 @default.
• W2016404251 cites W4252749312 @default.
• W2016404251 cites W4292028675 @default.
• W2016404251 doi "https://doi.org/10.1016/j.curtheres.2004.10.002" @default.
• W2016404251 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3964524" @default.
• W2016404251 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24672094" @default.
• W2016404251 hasPublicationYear "2004" @default.
• W2016404251 type Work @default.
• W2016404251 sameAs 2016404251 @default.
• W2016404251 citedByCount "25" @default.
• W2016404251 countsByYear W20164042512012 @default.
• W2016404251 countsByYear W20164042512017 @default.
• W2016404251 countsByYear W20164042512018 @default.
• W2016404251 countsByYear W20164042512020 @default.
• W2016404251 countsByYear W20164042512023 @default.
• W2016404251 crossrefType "journal-article" @default.
• W2016404251 hasAuthorship W2016404251A5002218114 @default.
• W2016404251 hasAuthorship W2016404251A5012219643 @default.
• W2016404251 hasAuthorship W2016404251A5033424480 @default.
• W2016404251 hasAuthorship W2016404251A5048924165 @default.
• W2016404251 hasAuthorship W2016404251A5074786040 @default.
• W2016404251 hasAuthorship W2016404251A5078432545 @default.
• W2016404251 hasBestOaLocation W20164042512 @default.
• W2016404251 hasConcept C126322002 @default.
• W2016404251 hasConcept C197934379 @default.
• W2016404251 hasConcept C2777075537 @default.
• W2016404251 hasConcept C2777214474 @default.
• W2016404251 hasConcept C2777448540 @default.
• W2016404251 hasConcept C2778375690 @default.
• W2016404251 hasConcept C2778889925 @default.
• W2016404251 hasConcept C2779225474 @default.
• W2016404251 hasConcept C2780026642 @default.
• W2016404251 hasConcept C2780325230 @default.
• W2016404251 hasConcept C501593827 @default.
• W2016404251 hasConcept C71924100 @default.
• W2016404251 hasConcept C86803240 @default.
• W2016404251 hasConcept C89423630 @default.
• W2016404251 hasConcept C90924648 @default.
• W2016404251 hasConceptScore W2016404251C126322002 @default.
• W2016404251 hasConceptScore W2016404251C197934379 @default.
• W2016404251 hasConceptScore W2016404251C2777075537 @default.
• W2016404251 hasConceptScore W2016404251C2777214474 @default.
• W2016404251 hasConceptScore W2016404251C2777448540 @default.
• W2016404251 hasConceptScore W2016404251C2778375690 @default.
• W2016404251 hasConceptScore W2016404251C2778889925 @default.
• W2016404251 hasConceptScore W2016404251C2779225474 @default.
• W2016404251 hasConceptScore W2016404251C2780026642 @default.
• W2016404251 hasConceptScore W2016404251C2780325230 @default.
• W2016404251 hasConceptScore W2016404251C501593827 @default.
• W2016404251 hasConceptScore W2016404251C71924100 @default.
• W2016404251 hasConceptScore W2016404251C86803240 @default.
• W2016404251 hasConceptScore W2016404251C89423630 @default.
• W2016404251 hasConceptScore W2016404251C90924648 @default.
• W2016404251 hasIssue "5" @default.
• W2016404251 hasLocation W20164042511 @default.
• W2016404251 hasLocation W20164042512 @default.
• W2016404251 hasLocation W20164042513 @default.
• W2016404251 hasLocation W20164042514 @default.
• W2016404251 hasOpenAccess W2016404251 @default.
• W2016404251 hasPrimaryLocation W20164042511 @default.
• W2016404251 hasRelatedWork W1989507260 @default.
• W2016404251 hasRelatedWork W2016404251 @default.
• W2016404251 hasRelatedWork W2091958019 @default.
• W2016404251 hasRelatedWork W2402900627 @default.
• W2016404251 hasRelatedWork W2566802278 @default.
• W2016404251 hasRelatedWork W2901861115 @default.
• W2016404251 hasRelatedWork W2977399540 @default.
• W2016404251 hasRelatedWork W3158300244 @default.
• W2016404251 hasRelatedWork W4360869619 @default.
• W2016404251 hasRelatedWork W4383383036 @default.
• W2016404251 hasVolume "65" @default.

• next